Major Finding: A dual function supracluster was engineered to increase radiosensitivity and antitumor immunity. Concept: Gold supraclusters carrying siRNA against LGALS1 (galectin-1) reshaped the ...

Merck announced today that pembrolizumab (Keytruda) injected subcutaneously is not inferior to intravenous (IV) dosing, currently the drug’s only approved route of administration. In the phase III ...

Search for other works by this author on: ...

1Fred Hutchinson Cancer Center, Seattle, WA.

Dive into how members of the Cukierman lab and their collaborators explore desmoplasia, the dense “shield” around tumors. Discover their groundbreaking 3D model that reveals the intricate “symphony” ...

Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy. Understanding the ...

Aging is the most important and well-recognized risk factor for cancer. Aging leads to systemic decline of physical fitness, significantly changing the macroenvironment from the early tumor initiation ...

2Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. 6Department of ...

Deep learning (DL) delineation of the prostate gland and prostate cancer detection on PSMA PET/CT: results from prospective, randomised, multi-centre pro-PSMA trial ...

1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China. 2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China. 3Tianjian Laboratory of Advanced ...

1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York ...

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Medicine, Weill Cornell Medical College, New York, New York. *Corresponding Author: Claire F.